Article Text

Download PDFPDF
Code ICH: reorganising stroke care for intracerebral haemorrhage
  1. Wendy Ziai1,
  2. Issam Awad2,
  3. Daniel Hanley3
  1. 1 Department of Neurology, Division of Neurocritical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2 Department of Neurosurgery, The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
  3. 3 Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to Professor Wendy Ziai; weziai{at}jhmi.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Code intracerebral haemorrhage: reorganising stroke care for intracerebral haemorrhage

Non-traumatic intracerebral haemorrhage (ICH) remains a high mortality and morbidity disease with few single intervention clinical trials demonstrating improvements in functional outcome. The failure of ICH trials to establish robust evidence useful for guidelines can be attributed to several factors. These include the timing of interventions which have remained incongruent with known timeframes for disease progression. In addition, trials have necessarily focused on single therapeutic interventions, while their likely benefit is greatest in synergy when combined with similar targeted interventions. There are impacts of the long recovery phase of ICH patients where subsequent health events may dilute the efficacy of an upfront treatment. While there have been a limited number of well-executed ICH trials that consistently show a mortality benefit, mortality reduction alone is insufficient. Finally, the design of ICH trials often uses selection criteria that lack generalisability, especially to higher disease severity and has been slow to adapt newer trial concepts such as platform trials and adaptive randomisation. These shortcomings create gaps between available trial evidence and real-world practice. Recent strategies implementing pragmatic acute care bundles into ICH care, including the prehospital phase may be improving this landscape. The main interventions evaluated in ICH care bundles so far are time metrics for earlier initiation of blood pressure (BP) control, reversal of anticoagulation if applicable, achieving blood glucose and body temperature targets and early consultation with neurosurgery. These can be facilitated by an acute alert system for protocol implementation, as in other medical emergency systems, conceptualised as an ‘ICH code’. Figure 1 shows gaps, challenges and some recommendations towards code ICH implementation.

Figure 1

Gaps, challenges and suggestions towards code ICH implementation. ICH, intracerebral haemorrhage.

Two studies evaluating care bundles for acute ICH management have been instrumental in promoting this concept. Parry-Jones et al conducted a single-centre implementation study of a goal-directed …

View Full Text

Footnotes

  • Contributors WZ is the guarantor and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: WZ and DH. Acquisition, analysis or interpretation of data: WZ and DH. Drafting of the manuscript: WZ. Critical revision of the manuscript for important intellectual content: WZ, IA and DH. Statistical analysis: none. Administrative, technical or material support: EH.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests WZ receives funds from the NIH and serves as an Associate Editor of Neurocritical Care, outside the submitted work. IA receives funds from the NIH and DoD and is a consultant to Neurelis and Ovid corporations, unrelated to ICH. DH receives funds from the NIH, DoD, Mental Wellness Foundation, Octapharma and Shear Family Foundation; is a consultant to Neurelis, Synaptogenix/Neurotrope, and receives fees for medicolegal consultation.

  • Provenance and peer review Not commissioned; externally peer reviewed.